Evidence map›Paper›PMID 41509338›Full record

ArticlebioRxiv : the preprint server for biology2025

Extracellular matrix regulates lineage plasticity in prostate cancer through YAP/TEAD.

Teng Han, Zhen Sun, Matthew Lange, Y Zoe Cho, Patrick Mcgillivray, Maren Büttner, Nathaniel R Kastan, Subhiksha Nandakumar, Huiyong Zhao, Sanyukta Oak and 19 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Teng HanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-8500-7652
Zhen SunHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Matthew LangeHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Y Zoe ChoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Patrick McgillivrayHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Maren BüttnerCalico Life Sciences LLC, South San Francisco, CA 94080, USA.
Nathaniel R KastanHoward Hughes Medical Institute and Laboratory of Sensory Neuroscience, The Rockefeller University, New York, NY 10021, USA.
Subhiksha NandakumarMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Huiyong ZhaoAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Sanyukta OakHoward Hughes Medical Institute and Laboratory of Sensory Neuroscience, The Rockefeller University, New York, NY 10021, USA.
Linda FongCalico Life Sciences LLC, South San Francisco, CA 94080, USA.
Wenfei KangMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Ning FanMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Jimmy ZhaoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Nazifa SalsabeelHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Harmanpreet KaurHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Ninghui MaoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Qing ChangAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Eric RosiekMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Eric ChanMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Murray TippingMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Nikolaus SchultzMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Pierre-Jacques HamardCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Elisa DeStanchinaAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Dana Pe'erProgram for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Richard KocheCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Zhenghao ChenCalico Life Sciences LLC, South San Francisco, CA 94080, USA.
A James HudspethHoward Hughes Medical Institute and Laboratory of Sensory Neuroscience, The Rockefeller University, New York, NY 10021, USA.ORCID 0000-0002-0295-1323
Charles L SawyersHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0003-4955-6475

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
SPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI David B. Solit · 2001 to 2026
$63.0M
Project 3: Analysis of intrinsic and extrinsic factors that promote prostate neuroendocrine differentiationP01CA265768 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Massimo Loda · 2022 to 2026
$13.4M
Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceR01CA193837 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2015 to 2025
$4.7M
NCI NIH HHS P01 CA265768NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS R01 CA193837
6 · The paper itself

Abstract

Treatment-related neuroendocrine prostate cancer (NEPC) is an increasingly frequent mechanism of resistance to androgen receptor pathway inhibitor (ARPI) therapy in prostate adenocarcinoma (PRAD). This lineage transition is dependent on upregulation of the NE-specifying transcription factor ASCL1, typically in a genetic background of

Identifiers

PMID41509338
PMCPMC12776418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.